Dupilumab in patients with diffuse type 2 CRSwNP had beneficial changes in nasal passage microbiota but did not alter gastrointestinal microbiota.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the ...

Chronic rhinosinusitis with nasal polyps increases the likelihood of developing coexisting conditions, such as asthma, ...

Patients with AD treated with dupilumab have a lower risk of various infections than those treated with methotrexate or cyclosporine.

A new international study led by researchers at McMaster University has identified the most effective and safest treatments ...

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, ...

Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data ...

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

A new international study led by researchers at McMaster University has identified the most effective and safest treatments ...

Dupilumab (Dupixent; Sanofi/Regeneron) has been approved to treat moderate to severe AD in children aged 6 months and older as well as in children who have asthma and eosinophilic esophagitis.

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...